Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flow from operating activities:
Net loss	$ (2,303,313)	$ (1,044,607)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation	221,078
Issuance of shares for services	155,486
Issuance of warrants for services	142,989
Accretion expense and day one derivative loss	879,416	120,531
Change in fair value of derivative liabilities	42,128	123,268
Changes in operating assets and liabilities:
Harmonized sales tax recoverable	7,328	2,574
Deposits and other receivables	(6,982)	26,427
Accounts payable and accrued liabilities	(423,015)	193,240
Net Cash used in operating activities	(1,284,885)	(578,567)
Cash flows from financing activities:
Issuance of shares, net of cash issuance costs	1,926,780
Proceeds from exercise of warrants		13,000
Proceeds from issuance of convertible notes, net		700,000
Due to shareholders		(39,795)
Net Cash provided by financing activities	1,926,780	673,205
Effect of foreign currency translation	126,069	(114,383)
Net increase in cash during the period	641,895	94,638
Cash, beginning of period	424,868	53,643
Cash, end of period	$ 1,192,832	$ 33,898